

19. (Amended) A histamine or serotonin binding compound or protein according to any one of [the preceding] claims 1, 2, 3 or 51 that binds specifically to histamine.

20. (Amended) The histamine or serotonin binding compound or protein of any one of [the preceding] claims 1, 2, 3 or 51 having an effector or reporter molecule attached hereto.

21. (Amended) The histamine or serotonin binding compound or protein of any [preceding claim] one of claims 1, 2, 3 or 51 that is derived from blood-feeding ectoparasites, spiders, scorpions or snakes and venomous animals.

~~In Claim 25, line 1, delete "the preceding";~~

~~line 2, after "claims" insert --1, 2, 3 or 51--.~~

~~In Claim 26, line 1, delete "the preceding";~~

~~line 2, after "claims" insert --1, 2, 3 or 51--.~~

~~In Claim 28, line 1, delete "the preceding";~~

~~line 2, after "claims" insert --1, 2, 3 or 51--.~~

~~In Claim 29, line 1, delete "the preceding";~~

~~line 2, after "claims" insert --1, 2, 3 or 51--.~~

~~In Claim 30, line 2, delete "the preceding";~~

~~line 2, after "claims" insert --1, 2, 3 or 51.~~

Please amend Claims 33 and 34 as follows:

33. (Amended) A vaccine comprising a histamine or serotonin binding compound or protein according to any one of claims 1[-10 or protein according to any one of claims 11-17] 2, 3 or 51.

a2  
cont.  
34. (Amended) The histamine or serotonin binding compound or protein according to any one of claims 1 [to 29 or composition of any one of claims 30 to 32] , 2, 3 or 51 for use in therapy.

Please delete Claims 35 to 38.

In ~~Claim 39~~, lines 1 and 2, delete "to 29" and insert --, 2, 3 or 51;

line 3, after "material" insert --,--.

In Claim 40, line 1, delete "to 29" and insert --, 2, 3 or 51--.

In Claim 41, line 1, delete "to 29" and insert --, 2, 3, or 51--.

In Claim 42, lines 1 and 2, delete "to 29" and insert --, 2, 3 or 51--.

In Claim 43, lines 1 and 2, delete "to 29" and insert --2, 3 or 51--.

Please amend Claim 44 as follows:

44. (Amended) A method for treating or preventing inflammation or allergic reaction in humans or animals, comprising administering a therapeutically effective amount [The use] of a histamine or serotonin binding compound according to any one of claims 1 [to 29] , 2, 3 or 51 in conjunction with a pharmaceutically-acceptable carrier [in the manufacture of a medicament for the treatment or prevention of inflammation or allergic reaction in humans or animals].

In Claim 45, line 2, delete "to 29" and insert --, 2, 3 or 51--.

In Claim 47, line 2, delete "either of claims 45 or 46" and insert --Claim 45--.

In Claim 49, line 1, delete "either of claims 47 or 48" and insert --Claim 47--.

Please amend Claim 50 as follows:

a<sup>4</sup> 50. (Amended) A transgenic animal that has been transformed by a nucleic acid molecule according to [either of] claim[s] 45 [or 46 or vector according to either of claims 47 or 48].

Please add the following new Claim 51:

51. A protein selected from the group consisting of the Ra-Res amino acid sequence given in Figure 5, the Av-HBP amino acid sequence given in Figure 6, the Ih/Bm-HBP amino acid sequence given in Figure 7, the Ih/Bm-HBP2 amino acid sequence given in Figure 8, the Ih/Bm-HBP3 amino acid sequence given in Figure 9, the Ih/Bm-HBP4 amino acid sequence given in Figure 10, the Ih/Bm-HBP5 amino acid sequence given in Figure 11, functional equivalent derivatives or fragments thereof.

REMARKS

The above amendments are submitted herewith to reduce multiple dependencies and to conform the claims more closely to U.S. practice.

The amendments made herein are with respect to Claims 1-50, which claims were amended during the pendency of the International Application. A copy of Claims 1-50, which are included in the International Preliminary Examination Report, are enclosed herewith and attached hereto.